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Abstract
Background: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized
by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination
forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The
chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in
several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity
of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and
therapeutic monitor for Gaucher’s disease.
Methods: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy
controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also
correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages
in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha
(TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out
(n = 10) versus wild-type mice (n = 10).
Results: Plasma chitotriosidase activity in cystinotic patients (0–3880, median 163 nmol/ml/h) was significantly elevated
compared to healthy controls (0–90, median 18 nmol/ml/h) and to CKD patients (0–321, median 52 nmol/ml/h),
P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations;
however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency.
Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8),
P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant
in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage
supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than
in the wild-type mice, P = 0.003.
Conclusions: This study indicates that cystine crystals are potent activators of human macrophages and that
chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor
for nephropathic cystinosis.
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Background
Nephropathic cystinosis (NC) is the prototype disorder for
lysosomal transporter protein defects. CTNS gene muta-
tions cause deficiency of cystinosin, the protein that trans-
ports cystine out of the lysosomes, resulting in the
accumulation and crystallization of cystine in virtually all
body cells. NC patients are asymptomatic at birth and
usually develop normally during the first six months of
life, where after they start to present with renal Fanconi
syndrome. If not treated, renal failure invariably develops
within the first decade of life [1].
The aminothiol cysteamine is the only specific treatment
known today. It depletes lysosomal cystine through the
formation of cysteine and the mixed disulfide cysteamine-
cysteine complex which exits the lysosome via an intact
PQLC2-transporter [2]. Cysteamine slows down the de-
terioration of the kidney function and postpones or even
prevents extra-renal damage [1].
Elevated white blood cell (WBC) cystine concentration
is the diagnostic cornerstone, as the pathognomonic cor-
neal cystine crystals can frequently be missed in children
younger than 18 months and genetic testing usually takes
a longer time [3]. WBC cystine assay was introduced by
Oshima et al. who used [14C] cystine and E.coli cystine-
binding protein [4]. Currently most laboratories switched
to HPLC [5] or LC-MS/MS [6] methods to avoid working
with radioactivity. While biochemical cystine determin-
ation can be well-standardized, the major source of impre-
cision is attributed to the WBC isolation and storage [7].
Furthermore, blood for cystine assay must be taken six
hours after the last cysteamine dose which is not always
clinically feasible. Finally, it is currently unknown whether
WBC cystine levels adequately represent cystine accumu-
lation in tissues.
Chitotriosidase was first associated with marked lyso-
somal storage in Gaucher’s disease patients [8]. Later its
elevation was detected in many other lysosomal storage
disorders (LSDs) [9] and also in multiple other diseases
as β-thalassemia [10] and sarcoidosis [11].
Due to the absence of its natural substrate (chitin) in
mammals and its secretion mainly by activated macro-
phages, chitotriosidase was rapidly linked to innate im-
munity as a defense mechanism against chitin coated
pathogens [12]. However, its elevation in response to
storage and chronic inflammatory disorders clarified its
other nature as a marker of macrophage activation.
Despite the fact that about 6% of Caucasians have
complete enzyme deficiency due to homozygosity to the
24-bp duplication mutation at exon 10 of the chitotriosi-
dase gene (CHIT1) [13], plasma chitotriosidase activity
has been established as a screening marker and thera-
peutic monitor for enzyme replacement therapy in
Gaucher’s disease [14]. Further studies reported the val-
idity of the clinical use of chitotriosidase activity in the
screening of other lysosomal disorders as Niemann-Pick
disease and Gangliosidosis M1 [15] and for therapeutic
monitoring of male Fabry patients [16]. Recently, chito-
triosidase elevation was documented in a case-report of
nephropathic cystinosis [17], and it was suggested that it
could be of value in monitoring cysteamine therapy.
In the current study, we aimed to evaluate the potential
of plasma chitotriosidase activity for the clinical screening
and therapeutic monitoring of NC patients. As a proof of
principle we tested our hypothesis on the cellular level in
control human macrophages and in the plasma of the
murine cystinotic model.
Methods
Patients
Forty five NC patients were recruited over the period:
November 2010- April 2013. Twenty three Egyptian pa-
tients (10 m-16y, median 3.8y) were recruited at the Center
of Pediatric Nephrology and Transplantation (CPNT),
Cairo University Children’s Hospital, Egypt and 22
European patients (2-49y, median 26.5y) were recruited
at Pediatric Nephrology Clinics, University Hospital
Leuven, K.U. Leuven, Belgium and Pediatric Nephrol-
ogy and Internal Medicine departments, Radboud Uni-
versity Medical Center, Nijmegen, the Netherlands.
Nine Egyptian patients were newly-diagnosed (10-28 m),
while the rest of Egyptian and all European patients were
already on cysteamine therapy. Chitotriosidase activities in
cystinotic patients were compared to 54 healthy pediatric
controls (1-16y, median 4.8y), 33 healthy adult controls
(22-48y, median 36y), 24 renal pediatric controls: 12 with
renal Fanconi syndrome after excluding NC (2-5y, median
3y) with chronic kidney disease (CKD 1-4) and 12 with
end stage renal disease (ESRD, CKD 5) due to a variety of
other causes (2-12y, median 6y), 15 patients with diabetic
nephropathy (CKD 1–4, 26-46y, median 32y) and 15 pa-
tients with ESRD (CKD 5, 19-58y, median 41y). The
current study was approved by the Institutional Research
and Ethical Committee and written informed consents
were obtained from healthy controls and patients or legal
guardians in case of minors.
Ctns knocked-out mice
Blood was collected from the retro-orbital plexus of ten
C57BL/6 Ctns(−/−) mice (12-15 m, median 13 m) and ten
wild-type mice (12-15 m, median 12 m) with heparinized
capillaries. Blood was centrifuged 20 min at 5000 rpm and
plasma was kept at −80°C till assayed.
L-cystine crystal preparation
120 mg of L-cystine (Fluca) was dissolved in 200 ml of dis-
tilled water through boiling while stirring. Solution was
left to stand overnight. After centrifugation, supernatant
was transferred to another container as fully saturated
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cystine solution, while the crystallized deposit was kept in
5 ml of saturated solution. After vigorous mixing 0.5 ml
was transferred and dried in a vacuum centrifuge. Accord-
ing to the pellet’s weight the crystal concentration was ad-
justed to 10 mg/ml. Crystal size was mostly below 10 μm.
Cystine saturated and crystal stock solutions were kept at
4°C till used.
Monocyte maturation
Heparinized blood was collected from healthy donors.
Monocytes were separated with CD14 magnetic micro-
beads according to the supplier’s protocol (MACS, Miltenyi
Biotec) and incubated in RPMI-1640 (Lonza) supplemented
with 10% FCS, 2 mM L-glutamine and 50 μg/ml gentamy-
cin. Cells were seeded at a concentration of 1-2million/ml,
while adding 0.1 μg/ml GM-CSF (Gentaur) and 50 nmol/
ml β-mercaptoethanol. After 3 days half amount of the
culture medium was replaced with fresh medium contain-
ing GM-CSF (0.2 μg/ml) and β-mercaptoethanol (50 nmol/
ml). After another four days differentiated macrophages
were harvested with trypsin (170 U/ml) + EDTA (200 mg/L)
(Lonza) and immediately used.
Macrophage exposure to cystine crystals
Mature macrophages were seeded in 25 cm2 flasks at a
density of 100,000 cells/ml, left to stand for 2 hours,
then washed with PBS to eliminate non-adherent cells.
Cystine crystals were washed three times in cystine satu-
rated solution. Supernatant was discarded and cystine
saturated culture medium was added (Culture stock so-
lution with crystal concentration 10 mg/ml), then two
experiments were performed:
Experiment 1: There was no previous data available for
the suitable amount of cystine crystals to stimulate
macrophages, therefore we adapted a wide
concentration range (0–200 ug/cm2) guided by
similar experiments with other crystals as calcium
oxalate [18]. Cystine crystal stock solution was
mixed and transferred to fresh medium in
concentrations ranging from 0 to 200 μg/cm2
(0, 1, 5, 25, 100 and 200 μg/cm2), a triplicate of each
concentration was performed in two separate
experiments. Adherent macrophages were incubated
with cystine crystals at 37°C, 5% CO2 for three
hours, and then washed with PBS to eliminate
excess crystals and fresh medium was added. At
determined intervals from the crystal elimination
(0, 4, 8, 24 and 48 hours) 300 μl of culture fluid was
sampled, centrifuged and supernatant kept at −80°C
for TNF-α and chitotriosidase measurements.
Resulting values were corrected for medium volume
changes.
Experiment 2: Adherent macrophages were incubated
with crystal solution at a fixed concentration of
100 μg/cm2, and then washed as previously
described. At determined intervals: 0, 8, 24, 48 and
72 hours cells were harvested in duplicate. In the
same experiment control macrophages were
harvested at the same intervals. All pellets were kept
immediately at −80°C till assaying chitotriosidase
activity.
Microscopy
Macrophages were visualized directly and after 48 hours
by inverted phase contrast microscopy within culture
flasks after incubation and washing excess crystals (DM-
IL-LED, Leica microsystems).
TNF-α immunoreactivity
TNF-α was measured in culture supernatant by a sand-
wich ELISA technique according to the manufacturer’s
protocol (BD Pharmingen).
Chitotriosidase enzyme activity
Either plasma, culture supernatant or macrophage cell-
lysate were used as samples. Macrophage lysis buffer
included 1% IGEPAL CA-630, 1% SDS, 12 mM Na deoxy-
cholate, 0.6 mM PMSF, 1 μg/ml aprotinin and 1 mM Na
orthovanadate (Sigma). Activity was measured as previ-
ously described [8]. Results were expressed as nmol/ml/h
for plasma and nmol/mg pellet protein/h for supernatant
and cell-lysate.
Chitotriosidase genotype
Being a common mutation in many ethnicities and the
main cause of chitotriosidase deficiency worldwide [13],
DNA analysis for detecting the 24-bp duplication muta-
tion within exon ten of CHIT1 gene was performed for
cystinotic patients. PCR was performed as previously de-
scribed [13] resulting in the formation of a 75-bp band
in the wild-type, a 99-bp band in the homozygously mu-
tated and both in the heterozygous. Healthy controls for
macrophage experiments were confirmed as being wild-
type.
WBC cystine assay
Ten ml of blood was collected from NC patients. WBC
were separated using dextran 3%, and pellets were kept
at −80°C with 150 μl of N-ethylmaleimide and 50 μl of
12% sulfosalicylic acid till assayed. Cystine was quanti-
fied by LC-MS/MS (Micromass, Waters) as previously
described [6].
Statistical analysis
Unless otherwise stated all results were expressed as range
and median. Differences were analyzed using a two-tailed
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Mann–Whitney U test with the Finner adjustment for
multiple testing [WinPepi statistical software package].
Pearson correlation coefficient (r) was used for testing cor-
relations and P < 0.05 was set as the level of significance.
Results
Plasma chitotriosidase activity
Chitotriosidase levels in 45 cystinotic patients ranged from
0 to 3880 (median 163 nmol/ml/h), which were signifi-
cantly different from 87 healthy controls ranging from 0 to
90 (median 18 nmol/ml/h), P < 0.001, including 54 healthy
pediatric controls ranging from 0 to 72 (median 14 nmol/
ml/h) and 33 healthy adult controls ranging from 0 to 90
(median 31 nmol/ml/h). Levels in the cystinotic patients
were also significantly different from the 54 CKD controls
ranging from 0 to 321 (median 52 nmol/ml/h), P < 0.001.
Renal controls consisted of 24 pediatric patients ranging
from 2 to 144 (median 39 nmol/ml/h) and 30 ranging from
0 to 321 (median 73 nmol/ml/h). Table 1 summarizes chit
otriosidase values for different subgroups of patients and
controls. Poorly controlled cystinotic patients with ESRD
demonstrated very high chitotriosidase values (899, 962,
1346, 1487 and 3880 nmol/ml/h), P = 0.002 compared to
the ESRD control group.
Among our series, nine cystinotic patients were newly-
diagnosed. Their chitotriosidase activity ranged from 0 to
288 (median 122 nmol/ml/h), while their age matching
healthy and CKD controls ranged from 0 to 49 (median
15 nmol/ml/h), P < 0.001 (Figure 1).
Chitotriosidase levels were generally higher in the 23
Egyptian patients ranging from 0 to 3880 (median
288 nmol/ml/h) compared to 22 European patients, in
whom they ranged from 0 to 1487 (median 70 nmol/ml/
h). On the other hand, WBC cystine levels in the ten mea-
sured Egyptian patients on treatment ranged from 1.5 to
15.3 (median 4.6 nmol ½ cystine/mg protein), while in the
Table 1 Chitotriosidase activity in control groups and cystinotic patients
Group N Age in years range
(median)
Chitotriosidase activity nmol/ml
plasma/h range (median)
P values
All normal controls 87 1-48 (12) 0-90 (18)
Pediatric normal controls 54 1-16 (4.8) 0-72 (14)
Adult normal controls 33 22-48 (36) 0-90 (31) <0.001 with pediatric normal controls
All renal controls 54 2-58 (22) 0-321 (52) <0.001 with all normal controls
Pediatric renal controls 24 2-12 (4.6) 2-144 (39) <0.001 with pediatric normal controls
Fanconi syndrome 12 2-5 (3) 5-44 (19) 0.60 with pediatric normal controls
ESRD 12 2-12 (6) 2-144 (67) <0.001 with pediatric normal controls
<0.001 with pediatric Fanconi syndrome
Adult renal controls 30 19-58 (38) 0-321 (73) <0.001 with adult normal controls
Microalbuminuria 15 26-46 (32) 8-143 (60) 0.008 with adult normal controls
ESRD 15 19-58 (41) 0-321 (87) <0.001 with adult normal controls
0.40 with diabetic nephropathy
All controls with ESRD 27 2-58 (22) 0-321 (75)
All controls below 5 years 39 0.5- 4.5 (2.2) 0-49 (15)
Cystinosis patients 45 0.8-49 (13) 0-3880 (163) <0.001 with all normal controls
<0.001 with all renal controls
All pediatric patients 25 0.8-16 (3.8) 0-3880 (268) <0.001 with pediatric normal controls
<0.001 with pediatric renal controls
All adult patients 20 18-49 (28) 0-1487 (78) <0.001 with adult normal controls
0.44 with adult renal controls
Cysteamine treated patients
Cystine* <1 11 17-49 (34) 18-342 (52) 0.71 with all renal controls
Cystine* >1 and <4 13 2-38 (24) 0-843 (245) 0.006 with all renal controls
Cystine* >4 12 3.5-36 (10.5) 84-1487 (788) <0.001 with all renal controls
Cystinosis patients with ESRD 5 8-24 (12) 899-3880 (1346) 0.002 with all controls with ESRD
Newly diagnosed patients 9 0.8-2.7 (1.6) 0-288 (122) <0.001 with all controls <5 years
*WBC cystine in nmol ½ cystine/mg protein; ESRD, end stage renal disease.
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22 European patients it ranged from 0.27 to 4.1 (median
1.1 nmol ½ cystine/mg protein), r = 0.8 and 0.78 with cor-
responding chitotriosidase values, respectively. Combined
Pearson correlation coefficient was r = 0.8, P < 0.001
(Figure 2).
Over the last year we further evaluated a naïve set of
suspected patients (n = 13) who were referred to our
laboratory for WBC cystine assay. WBC cystine levels
for nine negative cases ranged from 0.06 to 0.36 nmol ½
cystine/mg protein, while their chitotriosidase activities
ranged from 7 to 43 nmol/ml/h. As for the four positive
cases their cystine levels ranged from 3.9 to 12.3 nmol ½
cystine/mg protein, and their chitotriosidase activities
ranged from 76 to 373 nmol/ml/h.
Chitotriosidase genotype
Thirty six patients were analyzed for the presence of the
24-bp duplication. We found 21 wild-type, 13 heterozy-
gous and two homozygous for the mutation. Three pa-
tients were below detection limit for chitotriosidase in our
study, two of them were homozygous for the mutation
(one Egyptian and one European) and the third (a 2 year’s
old treated European child) was heterozygous (Figure 1).
Macrophage activation by cystine crystals
Uptake of cystine crystals by mature macrophages was
demonstrated by phase contrast microscopy (Figure 3).
Over 95% of macrophages were still strongly attached
to the culture flask surface after 48 hours of crystal
elimination denoting cell viability. Looking for direct
evidence of macrophage activation after crystal uptake,
TNF-α was measured at predetermined intervals. The
detected peak level for TNF-α was eight hours after
crystal elimination, and the maximum response was ob-
tained with the highest crystal concentration used
Chitotriosidase (nmol/ml plasma/h)
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Normal controls
n= 87
Renal controls
n= 54
New cases
n= 9
NC patients
n= 45
Controls <5 y
n= 39
P<0 001
P<0 001
P<0 001
Figure 1 Plasma Chitotriosidase activities in different test groups. Normal pediatric controls (Δ), normal adult controls (▲), pediatric
controls with renal Fanconi syndrome (○), pediatric controls with ESRD (●), adult renal controls with microalbuminuria (□), adult renal
controls with ESRD (∎) and Cystinotic patients; European (♦) and Egyptian (◊). Forty five cystinotic patients were compared to 54 healthy
pediatric controls, 33 healthy adult controls, 24 renal disease pediatric patients (12 with Fanconi syndrome and 12 with ESRD) and 30 renal
disease adult patients (15 with albuminuria and 15 with ESRD). Nine newly diagnosed Egyptian patients were compared to all controls below
5 years of age (26 normal and 13 renal). Averages of duplicates were used. Horizontal bars represent the median value for each group.
0
200
400
600
800
1000
1200
1400
1600
0 5 10 15 20
Cystine in WBC (nmol ½ cystine/mg protein)
Chitotriosidase (nmol/ml plasma/h)
Y= 53.5+ 112.3X
r = 0.8
Figure 2 Correlation of plasma chitotriosidase activity with
WBC cystine assay in 32 cystinotic patients, 22 Europeans (◊)
and 10 Egyptians (◊), all on different doses of cysteamine
therapy. Four treated Egyptian patients were not sampled for WBC
cystine at the same time of the chitotriosidase sampling, so they
were not included in the analysis. Pearson correlation coefficient
was used.
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(200 μg/cm2), which was about ten folds the zero level
response (Figure 4).
Chitotriosidase activity in macrophage cell culture
Chitotriosidase activity was increased in the supernatant
and cell-lysate of macrophages incubated with cystine
crystals (Figure 5A and B). Activity in the supernatant
was higher than in cell-lysate when referred to pellet’s
protein content indicating the enzyme rapid extracellular
release. Chitotriosidase activities were significantly dif-
ferent from zero level crystal concentration at 48 hours
for most concentrations tested, however a trend was ob-
served already after 24 hours.
Chitotriosidase activity in mice
In an attempt to consolidate our hypothesis in a different
species, we found a significant difference between plasma
chitotriosidase levels in Ctns(−/−) mice (100–198, median
137 nmol/ml/h, n = 10) and Ctns(+/+) mice (61–82, me-
dian 73 nmol/ml/h, n = 10), P = 0.003.
Discussion
Macrophage activation has been previously reported in
many LSDs. Although exact mechanisms are largely un-
known, this might reflect the altering signaling pathways
in response to storage materials [19]. Furthermore, dif-
ferent types of crystals such as calcium oxalate [18] and
monosodium urate [20] were shown to stimulate human
macrophages. Tissue macrophages harboring cystine
crystals have been demonstrated in cystinotic patients
long ago [21,22]. Several immune enhancing molecules
such as interferon-gamma, TNF-α and lipopolysacchar-
ide have all been shown to stimulate chitotriosidase ex-
pression in human macrophages [23]. We hypothesized
that in analogy to other crystal types cystine crystals are
not inert structures; they tend to activate macrophages
and as a consequence of the elicited activation, chitotrio-
sidase release can be detected clinically and confirmed
experimentally.
In our study, apart from a single newly-diagnosed cysti-
notic patient homozygous for the chitotriosidase defi-
ciency mutation, there was no overlap in chitotriosidase
values between the other twelve newly-diagnosed (8 in the
study group and 4 naïve patients) and age-matched con-
trols (39 in the study group and 9 naïve patients). This in-
dicates that chitotriosidase can be a helpful guide in
suspected individuals when WBC cystine measurement is
not immediately available, at least to prioritize patients as
high or low risk till properly diagnosed.
Many poorly controlled cystinotic patients achieved
very high chitotriosidase activities (Figure 1); the highest
value (3880 nmol/ml/h, 216 folds the median value of
normal controls) was observed in an eight years old
Egyptian boy with ESRD who died shortly after this
measurement. The median chitotriosidase value in the
45 cystinotic patients was about 10 folds the median of
normal controls. Apart from Gaucher’s disease which
has extremely high chitotriosidase values few other LSDs
achieve moderately high values comparable to cystinosis,
especially sphingolipidoses as Niemann-Pick, GM1 and
Krabbe [15,24].
Figure 3 A phase contrast micrograph of macrophages in
culture after exposure to cystine crystals. Many macrophages show
intracellular crystals (short arrows) and some show pseudopodia
(long arrows) to help in movement and engulfment of the crystals.
Figure 4 TNF-α concentrations in the supernatant of macrophage
cell culture after incubation with different concentrations of
cystine crystals (experiment 1). A triplicate of each concentration
was performed in two separate experiments. Concentrations were
expressed as pg/μg protein of macrophage pellets. Horizontal bars
represent the range of TNF-α values for each crystal concentration.
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European patients were generally much better thera-
peutically controlled than Egyptian patients. There was
no major difference in the severity of responsible muta-
tions as most mutations were truncating in both cohorts;
however, this difference in therapeutic response might be
due to the delayed diagnosis and suboptimal therapeutic
doses of cysteamine in Egyptian patients given the finan-
cial and logistical constraints in providing this orphan
drug in a developing country [25]. This was evident from
WBC cystine levels in each group. As it could be expected,
chitotriosidase activities were much lower in European
patients in accordance with the proposed role of chitotrio-
sidase as an alternative therapeutic monitor.
When compared to WBC cystine, plasma chitotriosi-
dase is much easier, faster, more economic, stable and
needs a much smaller sample (1 ml or less) which is
more convenient in young children. Furthermore, WBC
cystine is not the perfect measure of therapeutic re-
sponse, as polymorphonuclear leucocytes harboring cyst-
ine are short living cells (≈12 hours); therefore, WBC
cystine represents relatively a short time of therapeutic
control. Hypothetically, if a patient complies strictly with
A
0
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40
50
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80
Chitotriosidase in pellets
(nmol/mg pellet protein/h)
Hours80 24 48 72
B
Cystine crystal load
0 ug/cm2
100 ug/cm2
Figure 5 Chitotriosidase activity in the supernatant and cell-lysate of macrophages after incubation with cystine crystals.
(A) Chitotriosidase activity in the supernatant of macrophages incubated with different concentrations of cystine crystals (experiment 1).
(B) Chitotriosidase activity in the cell-lysate of macrophages incubated with 100 ug/cm2 cystine crystals (experiment 2). Results were represented
as averages and standard deviations of 2 independent experiments in triplicate for experiment 1 and in duplicate for experiment 2. Enzyme
activities for both experiments were expressed as nmol enzyme activity/mg pellet protein/h. *represents P < 0.05 with the zero level
crystal concentration.
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cysteamine treatment a few days before the assay, he
may appear properly controlled regardless of previous
compliance status. Chitotriosidase, on the other hand, is
produced by macrophages which are longer living cells
(months to years), and therefore should provide a better
notion about therapeutic response over a longer time
period. For confirming this statement a more extended
longitudinal study is currently underway to better correl-
ate clinical course under cysteamine therapy with chito-
triosidase levels.
In newly-diagnosed patients, although chitotriosidase
levels were significantly higher than age-matched con-
trols; there was a poor correlation with WBC cystine in
cases diagnosed below two years of age. This could be
explained by the relative immaturity of human macro-
phages in infants and young children [26] and better
preservation of kidney function, therefore necessitating
cautious interpretation of chitotriosidase levels in this
age group.
Two of our patients (2/45 or 4.4%) were homozygous
for the 24-bp duplication mutation in accordance with
the previously reported prevalence [13]. The third pa-
tient having values below the detection limit (A properly
controlled 2 years old European child) was heterozygous.
The second sample taken few months later showed
higher level of chitotriosidase (within the enzyme detect-
able range) that also corresponded with a higher WBC
cystine value.
We have to stress here that chitotriosidase activity will
not replace the WBC cystine assay in NC diagnosis;
however, we believe that it is a useful clinical screening
test and a promising therapeutic monitor. Concerns
about false negative screening when the CHIT1 gene is
homozygously mutated can be met with setting a lower
cut-off limit for the assay, below which the chitotriosi-
dase result is considered of no value and the suspected
patient should proceed anyway to WBC cystine assay or
to molecular diagnosis.
Although three of our newly diagnosed patients were
heterozygous for the CHIT1 mutation, their plasma chit-
otriosidase activities (78, 122 and 138 nmol/ml/h) were
clearly above their age-matched controls (0–49 nmol/
ml/h, n = 39). Furthermore, recent evidence in Gaucher’s
disease implies that chitotriosidase activities in the het-
erozygous patients, although significantly decreased
compared to the wild-type, respond to treatment in a
very similar way. Chitotriosidase activities in the wild
type Gaucher’s patients after one year of starting enzyme
replacement therapy decreased by 79 ± 13% of base line
values, while in a similar cohort of heterozygous patients
the percent of decrease was also similar 77 ± 16% [27].
Likewise, Gaucher patients with the common CHIT1
polymorphism p.G102S were reported to have a similar
decline in chitotriosidase activity in response to optimal
enzyme replacement therapy (72 ± 18% in the heterozy-
gous and 76 ± 20% in the homozygous) [27].
We noticed significant elevations in chitotriosidase ac-
tivity in control subjects with ESRD compared to normal
pediatric and adult controls (P < 0.001). This could be
explained by the fact that macrophage infiltration of
renal tissue is a common feature of most human chronic
kidney disease and that pathogenic M1 subpopulations
are implicated in the pathology of renal fibrosis [28].
However, chitotriosidase levels in ESRD controls were
still much lower compared to NC patients with the same
degree of renal disease because macrophage activation in
cystinosis is a global pathology and not just restricted to
the kidney.
There are two possible mechanisms of macrophage ac-
tivation by cystine in cystinotic patients. The first is the
gradual accumulation of cystine inside macrophages up
to crystallization because macrophages also have cysti-
nosin defect and cannot get rid of their lysosomal cyst-
ine similar to other cell types. The second mechanism is
the engulfment of dying and apoptotic cells in different
tissues with ready formed cystine crystals inside or
around these cells and because macrophages have the
same pathology they cannot dissolve these phagocytized
crystals.
We tried to address both mechanisms initially and
used cystine dimethyl ester (CDME) as a rapid loading
molecule of cystine into cultured macrophages; however,
this molecule was toxic to macrophages and we couldn’t
achieve our target with non-toxic levels. Using patients
macrophages was not feasible because of the high
amount of blood required for the experiments. Thus, we
addressed the second mechanism through the direct in-
cubation of control human macrophages with different
concentrations of cystine crystals in-vitro and succeeded
in demonstrating the phagocytosis of cystine crystals,
the activation of macrophages only by the crystals and
the release of chitotriosidase enzyme.
TNF-α, being an established marker of macrophage
activation and a direct stimulant of chitotriosidase re-
lease [23], was measured sequentially in the supernatant
of macrophages exposed to cystine crystals. TNF-α
quantified response was correlated with the crystal con-
centration used (Figure 4), denoting the evident activa-
tion of macrophages upon exposure and engulfment of
crystals. Macrophage activation was further confirmed
through the elevation of chitotriosidase activity in both
supernatant and cell-lysate. In fact, this was demon-
strated in control macrophages that were capable of pro-
cessing cystine, while in-vivo this stimulation might be
even more pronounced in cystinotic macrophages.
Recently, Principe et al. attributed NC with the inflam-
masome system activation and argued that the inflamma-
tion caused by cystine crystals could be responsible for the
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rapid progression to ESRD in cystinosis unlike other types
of hereditary Fanconi syndromes [29]. Similar observation
was made by Knauf et al. who demonstrated the import-
ance of the inflammasome mediator NALP3 in the renal
injury and fatality of mice with oxalate nephropathy [30].
Okamura et al. further elucidated the role of cysteamine
treatment in reducing macrophage accumulation in the
renal interstitium of mice exposed to chronic renal injury
and reducing the generation of reactive oxygen species in
these macrophages [31]. Thus, the clinical assessment of
macrophage activation in NC as an indicator of disease ac-
tivity and/or therapeutic response seems to be a promising
approach. Measuring chitotriosidase activity in that regard
has many advantages compared to other circulating cyto-
kines, especially that the enzyme is long-living and very
stable, thus, less affected by acute infections or immuno-
suppressive drugs and it can be also measured in blood
spots [32].
The significant elevation of plasma chitotriosidase in
Ctns(−/−) mice indicates that its correlation with cysti-
nosis is not species specific. Although the median value
for the diseased was only double that of the wild-type,
this might refer to the shorter duration of the patho-
logical process and the relatively lower differential num-
ber of activated macrophages in mice [33].
The recent successful treatment of the murine cysti-
notic model by bone marrow cell transplantation [34]
and hematopoietic stem cell gene therapy [35], if proven
successful in human patients, will have a powerful impact
on the disease therapeutic strategy. However, the prob-
lem on how to evaluate the patient’s response post-
transplantation is not yet solved as estimating cystine
accumulation in tissue biopsies is too invasive for rou-
tine follow-up and measuring cystine in the donor’s
WBCs is useless. Chitotriosidase, on the other hand, is
rapid and non-invasive. When compared to a base-line
level it would represent the activity of the recipient’s
tissue macrophages and would be a reasonable indica-
tor of total body cystine load. Notably, chitotriosidase
enzyme was reported to show significant declines in re-
sponse to successful bone marrow transplantation in
Gaucher’s disease [14] and in β-thalassemia major [36].
Conclusions
In conclusion, plasma chitotriosidase activity was signifi-
cantly elevated in cystinotic patients at diagnosis over age
matched normal and renal controls and correlated with
WBC cystine assay for treated patients above 2 years of age.
Thus, chitotriosidase is a promising clinical biomarker and
therapeutic monitor in nephropathic cystinosis patients.
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